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[57] ABSTRACT 
Fluorescent 1-peptidylaminoalkanephosphonate derivatives, 
and their use in detecting and studying the distribution of 
serine proteases in cells and biological systems. 
20 Claims, No Drawings 
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1 
FLUORESCENT 1-
PEPTIDYLAMINOALKANEPHOSPHONATE 
DERIVATIVES 
2 
rahedron Lett., 1991, 32, 7333-7336; Wang et al., Tetrahe-
dron Lett., 1992, 33, 7667-7670; and Hamilton et al., 
Tetrahedron Lett., 1993, 34, 2847-2850). None of the diphe-
nyl peptide phosphonate esters mentioned above has fluo-
This is a continuation-in-part of applications Ser. No. 
08/324,809 filed on Oct. 18, 1994 now U.S. Pat. No. 
8,681,821. 
1. FIELD OF THE INVENTION 
5 rescent label attached to it. Tagging these inhibitors with 
fluorescent labels will render them excellent tools for study-
ing the distribution of serine proteases as well as measuring 
their quantities in natural killer cells, lymphocyte cells, and 
all other types of cells and biological systems. 
This invention relates to a novel class of fluorescent 10 
peptidyl derivatives of aromatic diesters of 
1-aminoalkanephosphonic acid useful for selectively inhib-
iting elastases, selectively inhibiting chymotrypsin-like 
enzymes, selectively inhibiting trypsin-like enzymes or for 
15 generally inhibiting serine proteases of many classes. 
2. DESCRIPTION OF THE RELATED ART 
BRIEF SUMMARY OF THE INVENTION 
We have found that diphenyl 1-pepidylaminoalkane-
phosphonate esters tagged with fluorescent groups such as 
fluorescein or sulforhodamine 101 are potent inhibitors of 
elastases, chymases, trypsin-like enzymes, granzymes, and 
other serine proteases. These fluorescent compounds are 
made by coupling fluorophores to peptidylphosphonates 
using spacer groups between the peptide and the fluoro-
phore. The spacer groups are inserted in order to prevent 
unfavorable steric interactions between the fluorophore and Serine proteases play critical roles in several physiologi-
cal processes such as digestion, blood coagulation, comple-
ment activation, fibrinolysis, viral infection, fertilization, 
and reproduction. Serine proteases are not only a physi-
ological necessity, but also a potential hazard if they are not 
controlled. Uncontrolled proteolysis by elastases may cause 
pancreatitis, emphysema. rheumatoid arthritis, bronchial 
inflammation and adult respiratory distress syndrome. 
Human polymorphonuclear leukocyte elastase may also be 
involved in blistering. Accordingly, potent and specific 
inhibitors of these proteases tagged with fluorescent mol-
ecules can be used to detect, localize, and quantify these 
enzymes in different types of cells and biological systems. 
Serine proteases inhibited by these fluorescent compounds 
can be detected at the single cell level. 
20 the active site of the protease. These compounds can be used 
to irreversibly label discrete granule-like regions of the 
natural killer (NK) cells. These fluorescent peptide phos-
phonates can be used to selectively inhibit serine proteases 
within whole cells. These fluorescent compounds can also be 
25 used to localize serine proteases inside cellular granules. These fluorescent compounds can also be used to selectively 
or generally inhibit serine proteases either in vitro or in 
biological systems. The properties of these fluorescent com-
pounds indicate that they will be excellent tools for the study 
of the distribution of serine proteases in lymphocytes and 
30 their role during cytotoxic T-lymphocyte killing. Use of 
these inhibitors with different peptide sequences with vary-
ing specificities and different fluorophores will allow the 
simultaneous detection of different proteases in cytotoxic 
lymphocytes as well as in other cells and biological systems. 
It is an object of this invention to find a novel group of 
specific fluorescent inhibitors for elastase, chymotrypsin, 
trypsin, and other serine proteases of similar substrate speci-
ficity and for serine proteases in general. Inhibitors are 
compounds that can reduce or elimnate the catalytic activity 
Many classes of phosphorus containing compounds have 
been prepared for use as inhibitors of serine proteases. One 35 
useful class reported by Oleksyszyn and Powers are peptidyl 
derivatives of a-aminoalkylphosphonate diphenyl esters 
(Irreversible Inhibition of Serine Proteases by Peptide 
Derivatives of ( a-aminoalkyl)phosphonate Di phenyl Esters, 
Oleksyszyn, J. and Powers, J. C., Biochemistry, 1991, 30, 
485-493). Other members of the class were described by 
Bartlett, P. A and Lamden, L. A, Bioorg. Chem., 1986, 14, 
356-377 and Lamden, L. A and Bartlett, P. A, Biochem. 
Biophys. Res. Commun., 1983, 112, 1085-1090. These com-
pounds are useful inhibitors for the serine proteases such as 
elastases, chymotrypsin, chymotrypsin-like enzymes, 
trypsin, trypsin-like enzymes, blood coagulation enzymes, 
kallikrein, plasmin, thrombin, and granzymes. Another class 
40 of the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 
amino acid residue on the carbonyl side of the split bond (Pl 
residue) is Lys, or Arg. Elastase and elastase-like enzymes, 
on the other hand, cleave peptide bonds where the Pl amino 
45 acid is Ala, Val, Ser, Leu and other similar amino acids. 
Chymotrypsin and chymotrypsin-like enzymes hydrolyze 
peptide bonds where Pl amino acid is Trp, Tyr, Phe, Met, 
Leu or other amino acid residues which contain aromatic or 
large alkyl side chains. All of the above enzymes have 
50 extensive secondary specificity and recognize amino acid 
residues removed from the Pl residue. 
of diphenyl peptide phosphonate esters was published by 
Oleksyszyn et al., 1994 (Novel Amidine-Containing Pepti-
dyl Phosphonates as Irreversible Inhibitors for Blood 
Coagulation and Related Serine Proteases Oleksyszyn, J., 
Boduszek, B., Kam, C.-M., and Powers, J. C.,J. Med. Chem. 
1994, 37, 226-231). This class included peptides with 
C-terminal phosphonate residues related to ornithine, lysine, 55 
arginine, or containing a C-terminal diphenyl ester of 
l-amino-1-( 4-amidinophenyl)methanephosphonate ( ( 4-
AmPh)GlyP(OPh)2) or l-amino-1-(4-amidinophenyl-
methyl)methanephosphonate (( 4-AmPhe t(OPh)2). These 
peptide phosphonates are specific and potent inhibitors of 60 
trypsin, thrombin, kallikrein, trypsin-like enzymes, coagu-
lation enzymes, and granzymes. A few other arginine and 
ornithine analogs and peptidyl phosphonates containing 
( a-amino-y-methoxybutyl)phosphonyl or ( a-amino-n-
hexyl)phosphonyl residues at the Pl site have been reported 65 
to be inhibitors of trypsin and thrombin (Fastrez et al., 
Tetrahedron Lett., 1989, 30, 6861-6864; Cheng et al., Tet-
It is a further object of this invention to define new 
fluorescent protease inhibitors, especially inhibitors for chy-
motrypsin and chymotrypsin-like enzymes, elastases, blood 
coagulation enzymes, tryptases, trypsin-like enzymes, 
kallikrein, and granzymes. Such inhibitors could be used to 
identify and localize new proteolytic enzymes encountered 
in research. The inhibitors of this invention would be useful 
for studying the role and the distribution of serine proteases 
found in cytotoxic T lymphocyte and natural killer cells. 
These inhibitors are useful for controlling, detecting, and 
measuring the active serine proteases involved in tumor 
invasion, blood coagulation and various inflammatory con-
ditions mediated by serine proteases. The inhibitors of this 
invention would be useful for studying the distribution and 
role of natural killer and cytotoxic lymphocyte serine pro-
teases. 
5,916,877 
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It is yet another object of this invention to define a novel 
group of specific inhibitors useful in vitro for inhibiting 
trypsin, elastase, chymotrypsin and other serine proteases of 
similar specificity. These inhibitors can be used in research 
Fluor is selected from the group consisting of 
to detect and measure undesired serine proteases found in all 5 
cells, tissues, and fluids. 
These and other objects are accomplished by the present 
invention which defines novel fluorescent peptidyl deriva-
tives of aryl diesters of 1-aminoalkanephosphonic acids. 
These fluorescent phosphonate derivatives are potent inhibi- 10 
tors of serine proteases including chymotrypsin-like 
enzymes, trypsin-like enzymes, elastase-like enzymes, and 
other enzymes with other substrate specificities. The fluo-
rescent peptide phosphonates are stable in buffer or plasma, 
and inhibit the serine proteases to give stable inhibited 15 
enzyme derivatives that can easily be detected using con-
focal microscopy and other ways. The fluorescent peptide 
phosphonates can be used in both in vitro and in vivo. 
DETAILED DESCRIPTION OF IBE 
INVENTION 
20 
Fluorescent peptidyl derivatives of aryl diesters of 
1-aminoalkanephosphonic acids have been found to be 
excellent inhibitors of several serine proteases including 
25 human leukocyte elastase, porcine pancreatic elastase, 
bovine chymotrypsin, granzyme A, granzyme K, bovine 
trypsin, and other serine proteases. The fluorescent diesters 
of 1-peptidylaminoalkanephosphonic acids are analogs of 
natural a-amino acids and are designated by the generally 
30 
accepted three letter abbreviations for the amino acid fol-
lowed by the superscript P. For example diphenyl N-(N-(5-
fl uoresceinyl)-5-carb amoylpen tanoyl) amino( 4-
amidinophenyl)methanephosphonate hydrochloride which 
is related to amidinophenylglycine is abbreviated as Fla-
35 Adp-(4-AmPhGlyt(OPh)2 . Fla is 5-fluoresceinylamino and 
Adp is adipoyl. 
40 
45 
HO 0 
(5-Substituted Flourescein) 
HO 0 
(6-Substituted Flourescein) 
(5-Substituted Tetramethylrhodamine) 
+ 
(CH3)2N N(CH3)2 
COOH (6-Substituted Tetramethylrhodamine) 
50 
HO 0 0 
The novel fluorescent peptidyl phosphonate inhibitors and 
related compounds contain a fluorophore (Fluor) bonded to 55 
the peptidyl phosphonate moiety through a spacer group and 
they have the following general structure: 
R 
~/z 
Flour-NHCO-Spacer-AA3-AA2- N p 
H ll"-z1 
60 
0 
65 
or an acceptable salt, wherein 
(5-Substituted Texas Red) 
(a) 
(b) 
(c) 
(d) 
(e) 
5,916,877 
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-continued 
(!) 
6 
The fluorophores used in this invention are those well 
known in the art of fluorescence. Examples of fluorophores 
include sulforhodamine (Texas Red), tetramethylrhodamine, 
rhodamine X, and fluorescein as well as their derivatives and 
5 tautomeric forms (see structures below). The fluorescent 
group can also be any fluorophore which can be attached to 
the spacer and can emit in the range of 350-700 nm. 
and 
( 6-Substituted Texas Red) 
(g) an aromatic fluorescent group with an em1ss10n 
maximum of 350 to 700 nm, 
Y is selected from the group consisting of H, COOH, 
and S03H, 
10 
15 
20 
Spacer is selected from the group consisting of 
(a)-CH2-CH2-CH2-CH2-CO-, 
(b) ---(CH2)n-CO-, 
where n=l to 12, 
AA3 and AA2 are the same or different and are selected 
independently from the group consisting of 
(a) a single bond, 
25 
30 
(b) a side chain blocked or unblocked amino acid 
residue with the Lor D configuration at the a-carbon 
selected from the group consisting of alanine, valine, 
leucine, isoleucine, praline, methionine, methionine 
sulfoxide, methionine sulfone, phenylalanine, 
tryptophan, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, 35 
norleucine, norvaline, alpha-aminobutyric acid, 
citrulline, hydroxyproline, ornithine, homolysine, 
and homoarginine, and 
(c) glycine, sarcosine, epsilon-aminocaproic acid, and 
beta-alanine, 40 
R is selected from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
side chain selected from the group consisting of 
glycine, alanine, valine, leucine, isoleucine, praline, 
methionine, methionine sulfoxide, methionine 45 
sulfone, phenylalanine, tryptophan, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, 
a 1 p ha - am n in ob u t yr i c acid, cit ru 11 in e, 50 
hydroxyproline, omithine, homolysine, and 
homoarginine, and 
(b) phenyl substituted with B, benzyl substituted with 
B on the phenyl, and C1 _6 alkyl substituted with B, 
B is selected from the group consisting of amidino 55 
(-C(=NH)NH2), guanidino (-NH-C(=NH) 
NH2), isothiureido (-S-C(=NH)NH2), and 
amino, 
Z and Z1 are the same or different and are selected 
independently from the group consisting of phenoxy, 60 
phenoxy substituted with J, phenoxy disubstituted with 
J, phenoxy trisubstituted with J, halogen, and cl-6 
alkoxy, and 
J is selected from the group consisting of halogen, C1 _6 
alkyl, C1 _6 perfluoroalkyl, C1 _6 alkoxy, and CN, 65 
Both Z and Z1 can't simultaneosly be C1 _6 alkoxy. 
HO OH 
(Lacatone Form) 
HO 0 
(Open Form) 
Flourescein 
(Lacatone Form) 
0 
(Open Form) 
Tetramethylrhodamine 
(Lactone Form) 
coo-
coo-
0 
7 
-continued 
(Open Form) 
Rhodamine X 
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irreversible inhibitors of elastase and elastase-like enzymes. 
The peptides with C-terminal phosphonate residues related 
to phenylalanine, other aromatic amino acids or amino acids 
with long aliphatic side chains are potent and specific 
5 inhibitors of chymotrypsin and chymotrypsin-like enzymes. 
The peptides with C-terminal phosphonate residues related 
to omithine, lysine, argiriine or containing a C-terminal 
diphenyl ester of amino( 4-amidinophenyl) 
10 methanephosphonate ((4-AmPhGlyt(OPh)2) or amino(4-
amidinophenylmethyl)methanephosphonate (( 4-AmPhe t 
(0Ph)2) are specific and potent inhibitors of trypsin and 
trypsin-like enzymes. 
Additional specificity as well as increased activation 
15 toward reaction with the enzyme can be introduced into the 
inhibitor molecule by variation of the amino acid sequence 
in the peptide portion of the structure. In fact there is a good 
agreement between the sequence of enzyme substrates such 
Fluorescent peptidyl derivatives of aryl diesters of 
1-aminoalkanephosphonic acids inhibit serine proteases by 
reaction with the active site serine to form phosphonylated 
enzymes, which due to similarity of the phosphorus atom to 20 
the tetrahedral intermediate formed during peptide 
hydrolysis, show remarkable stability. The enzyme catalytic 
apparatus is required to activate the phosphorus atom for 
nucleophilic substitution and reaction with enzyme. The 
activation is mainly due to precise interaction with the S1 25 
pocket of various serine proteases. The following figure 
shows the reaction course of a phosphonate with a serine 
protease. The phosphonate first binds to the enzyme (below 
left) and then reacts to form a covalent bond with the active 
site serine residue (below right). Slow aging can take place 
30 
with loss of the phenoxy group (below center). 
as a peptidyl p-nitroanilides or benzylthioesters and the 
sequence of an effective peptidyl phosphonate inhibitor. The 
best inhibitors have the sequence of the best peptidyl 
p-nitroanilide substrate for a particular enzyme. For 
example, a potent inhibitor for chymotrypsin is Fla-Adp-
PheP(OPh)2 (see Table 1) which has an amino acid sequence 
that is analogous to Suc-Phe-Leu-Phe-SBzl, an excellent 
substrate for these enzymes. With human leukocyte and 
porcine pancreatic elastases, a good inhibitor (Fla-Adp-Ala-
Ala-AlaP(OPh)2) has an amino acid sequence similar to 
Sue-Ala-Ala-Ala-NA and Boe-Ala-Ala-Ala-NA, two excel-
Substrate 
Binding Site 
Ser195 
I 
Active Site 
O-H- -His57 
R I /OPh 
R-CO-NH-CH-P 
11'-oPh 
0 
Active Site 
SI Ser195 
R J H-His57 
I / 
R-CO-NH-CH-P Aging 
11'-oPh 
,,o,, 
H H 
I I 
N N 
oxyanion 
hole 
Active Site 
SI Ser195 
R J H-His57 
I / 
R-CO-NH-CH-P 
ll'-0 -
,,0', 
H H 
I I 
N N 
oxyanion 
hole 
Peptides with a C-terminal phosphonate residue which is 
an analog ofvaline (e.g. ValP(OPh)2) are potent and specific 
lent substrates for porcine pancreatic elastase, and to the 
chloromethyl ketone, Ac-Ala-Ala-AlaCH2Cl, a good inhibi-
tor of human leukocyte elastase. Clearly it is possible to 
35 design good phosphonate inhibitors for serine proteases 
based on the peptide sequences found in other potent revers-
ible and irreversible inhibitors for those same serine pro-
teases reported in the literature. In this application, we 
40 
disclose methods of attached fluorescent groups to those 
potent phosphonate inhibitors. 
The following compounds are representatives of the 
invention: 
Diphenyl N-(N-(5-fluoresceinyl)-5-carbamoylpentanoyl) 
45 amino(benzyl)methanephosphonate hydrochloride {Fla-
Adp-(Phe t(OPh)2}. 
50 
Diphenyl N-(N-(5-fluoresceinyl)-5-carbamoylpentanoyl) 
aiino(4-amidinophenyl)methanephosphonate hydrochloride 
{Fla-Adp-( 4-AmPhGlyt(OPh)2}. 
Diphenyl N"'-(-(N-(5-Fluoresceinyl)-5-carbamoyl-
pentanoyl)lysylamino( 4-amidinophenyl)methanephospho-
nate hydrochloride {Fla-Adp-Lys-(4-AmPhGlyt(OPh)J. 
Dipheny 1 N"' -(N-( 5-Fluoresceiny 1)-5-carbamoylpent-
55 anoy 1)-E-tert-buty loxycabonyllysy lamina( 4-amidinopheny 1) 
methanephosphonate hydrochloride {Fla-Adp-Lys(Boc )-( 4-
AmPhGlyt(OPh)2}. 
Diphenyl N"' -(-(N-( 5-Fluoresceinyl)-5-carbamoylpent-
anoyl)theonylamino( 4-amidinophenyl)methanephosphonate 
60 hydrochloride {Fla-Adp-Thr-( 4-ArPhGlyt(OPh)J. 
Enzyme Kinetics 
Inactivation rates of serine proteases by fluorescent pep-
65 tidylphosphonates were measured by the incubation method. 
In each case the inactivation experiment was preceded by an 
enzyme assay in which the hydrolysis of peptide 
5,916,877 
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TABLE 1 
Rate Constants for Inhibition of Cathepsin G and Chymotrypsin by a 
Fluorescein Phosphonate Inhibitor' 
Inhibitor Cat Ge ChT° 
Fla-Adp-PheP(OPh)2 NI 147 ± 16 
p-nitroanilide substrates, catalyzed by chymotrypsin, PPE, 
HLE, and trypsin was measured in 0.1 M Hepes and 0.5 M 
NaCl (0.01 M CaC12 for trypsin), pH 7.5 buffer containing 
5-10% Me2 SO at 25° C. Stock solutions of substrates were 
prepared in Me2SO (20 mM) and stored at -20° C. Final 5 
substrate concentrations were 0.24 mM. Chymotrypsin 
activity was assayed with Suc-Val-Pro-Phe-NA. PPE was 
assayed with Sue-Ala-Ala-Ala-NA HLE was assayed with 
MeO-Suc-Ala-Ala-Pro-Val-NA and trypsin was assayed 10 
with Z-Arg-NA. The initial rates of hydrolysis were mea-
sured at 410 nm (E410=8800 M-1 cm-1 ) on a Beckman 35 
spectrophotometer after 25-50 µL of an enzyme stock 
solution was added to a cuvette containing 2.0 mL of buffer 
and 25 µL of substrate. 
Each inhibition reaction was initiated by adding a 50 µL 
aliquot of inhibitor (100--5000 µMin Me2 SO) to 0.5 mL of 
'Conditions were as follows: O.lM HEPES, O.SM NaCl, pH~ 7.5 buffer at 25° 
C. for ChT and PPE, and O.lM HEPES, 0.5M NaCl, 0.01 % Brij 35, pH~ 7.5 
buffer at 25° C. for cathepsin G. Cathepsin G was assayed with 5 mM 
Suc-Phe-Leu-Phe-sBzl in HEPES buffer containing 4% DMSO. Chymot-
rypsin was assayed with 5 mM Suc-Phe-Leu-Phe-NA in HEPES buffer 
containing 7% DMSO. Final enzymeconcentration in the inhibition mixture 
15 
was 1.2 µM for ChT and 0.04 µM for cathepsin G. 
bNo inhibition after 30 minutes incubation. 
a 0.1 M Hepes, 0.5 M NaCl (0.01 M CaC12 for trypsin), pH 
7.5 buffer containing 50 µL of a stock enzyme solution at 25° 
C. The enzyme stock solutions were 20 µM chymotrypsin, 20 
trypsin, and PPE in 1 mM HCl (pH 3), and 0.4-4 µM HLE The fluorescent compounds contammg an AmPhGly-1' 
residue were evaluated as inhibitors of several trypsin-like 
enzymes and were found to be a very specific and effective 
inhibitors (Table 2). For example granzyme A was most 
effective! y inhibited by Fla-Adp-Thr-( 4-AmPh Gly t ( 0 Ph)2 
(kobsaf(I)=720 M-1s-1), but this compound didn't inhibit the 
mast cell tryptase. The mast cell tryptase was inhibited by 
only one compound, while thrombin was effectively inhib-
ited by three of the four compounds tested. 
in 0.25 M NaAc and 1 M NaCl at pH 5.5. All the enzyme 
stock solutions were stored at -20° C. prior to use. Aliquots 
(25 µL) were withdrawn at various intervals and the residual 
enzymatic activity was measured spectrophotometrically as 25 
described above. Pseudo first-order inactivation rate con-
stants (kobsd) were obtained from plots of ln v /v 0 vs time and 
had correlation coefficients greater than 0.98. Each kobsd was 
calculated from 5-10 activity determinations which 
extended to 2-3 half lives. Control experiments were carried 
TABLE 2 
Fluorescein Inhibitors for Trvosin-Like Enzymes. 
inhibitor granzyme Aa tryptaseb trypsin a thrombinc 
Fla-Adp-(4-AmPhGly)"(OPh)2 210 ± 21 NI ct 210 ± 20 16 
Fla-Adp-Lys-( 4-AmPhGly)"(OPh)2 110 ± 2 0.5 80 ± 5 NI 
Fla-Adp-Lys(Box)-( 4-AmPhGly)"(OPh)2 630 ± 7 NI 120 ± 7 30 
Fla-Adp-Thr-(4-AmPhGly)"(OPh)2 720 ± 39 NI 280 ± 6 40 ± 1 
'Inhibition constants were measured in O.lM Hepes, O.OlM CaC12 , pH 7.5 at 25° C. 
"Tryptase inhibition constants were measured in O.lM Hepes, 10% glycerol and 10 mM heparin, 
pH 7.5 at 25° C. 
°Thrombin assays were conducted in O.lM Hepes and O.SM NaCl at pH 7.5 buffer at 25° C. The 
inhibition solutions contained approximately 2% DMSO for tryptase, trypsin, and thrombin, and 
7.6% DMSO for granzymeA. The tryptase was obtained from Dr. David A. Johnson. The inhibitor 
concentration ranged from 23 to 100 mM. The substrate used for each enzyme, except tryptase, 
was Cbz-Arg-SBzl (0.35-36 mM) in the presence of DTNB (0.7-72 mM).Tryptase kinetic 
constants were measured with Cbz-Lys-SBzl (0.1 mM) as the substrate in the presence of DTNB 
~0.2 mM). 
NI, no inhibition after 70 min of incubation with tryptase, and 25 min with any of the other 
enzymes. 
out in the same way as described above except Me2 SO was 
added in place of the inhibitor solution in Me2 SO. The initial 
rates of substrate hydrolysis did not change during the first 
60 minutes of incubation. These initial rates were used as v 0 
in the calculation of the inhibition rate constants. 
The specificity of these phosphonate inhibitors is depen-
55 dent upon the amino acid sequence in the peptide portion of 
the inhibitor. In each case, the amino acid sequence was 
chosen based on the specific sequence of a good substrate or 
inhibitor for the target enzyme. From our earlier work, it is 
also clear that the specificities of these fluorescent phospho-
Inhibitor Potency 
The fluorescent compound containing a PheP was evalu-
ated as an inhibitor of chymotrypsin and cathepsin G and 
was found to be a very specific inhibitor for chymotrypsin 
(kobsa/(1)=147 M-ls-1 (Table 1). 
60 nates compounds are parallel to those of nonfluorescent 
analogs and are dependent on the sequences of the peptide 
portions. Thus, previously reported phosphonate inhibitors 
can be converted into fluorescent inhibitors simply by 
attaching the Fla-Adp- moiety to the N-terminus of a peptide 
65 phosphonate. 
Another advantage of the Fla-Adp- phosphonates is their 
ease of synthesis and stability compared to previously 
5,916,877 
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reported FTC-Aca- derivatives. The compounds of the cur-
rent invention are much easier to synthesize and are more 
stable. The Fla-Adp-derivatives have an amide bond linking 
the Fluor and spacer (i.e. Fluor-NH-CO-CH2CH2-), 
while the earlier reported FTC-Aca- derivative have an urea 5 
or thiourea linkage between the Fluor and spacer (i.e. 
Fluor-NH-CO-NH-CH2- or Fluor-NH-CS-
NH-CH2-). Under the conditions required for the gen-
eration of the amidino phenylglycine derivative, the urea 
was less stable than the amide bond and gave lower yields 10 
of the desired products. In addition, there are many com-
mercially available dicarboxylic acids which can be used in 
the synthesis of analogs of the Fla-Adp- unit in the fluores-
cent phosphonate derivates of the present invention. 
15 
Synthesis 
The diphenyl 1-aminoalkanephosphonate esters are syn-
thesized from the appropriate aldehyde, benzyl carbamate, 
and triphenyl phosphite using previously a reported method 20 (Diphenyl 1-Aminoalkanephosphonates, Oleksyszyn, J., 
Subotkowska, L., and Mastalerz, P., Synthesis, 1979, 
985-986). For examJ?le, H-PheP(OPh)2, H-Mer(OPh)2, 
H-AlaP(OPh)2, H-Val (0Ph)2 can be prepared by reaction 
of phenylacetaldehyde, 3-(methylthio )propionaldehyde, 
acetaldehyde, 2-methylpropionaldehyde, respectively, with 25 
triphenylphosphite, benzyl carbamate, and acetic acid to 
give the corresponding Cbz-protected amino acid phospho-
nates (see scheme below) which can be deblocked by 
treatment with HBr/HOAc or hydrogenolysis. Likewise the 
chloro derivative, bis( 4-chlorophenyl) 1-(N- 30 
benyzy loxycarbony lamina )-3-me thy 1 thioprop ane-
phosphonate, Cbz-MetP( 4-Cl-C6H40)2 can be prepared 
from tris( 4-chlorophenyl)phosphite, benzylcarbamate, and 
3-methylthiopropionaldehyde in the presence of acetic acid. 
R-CHO 
Bz!OCONH2 
P(OPh)3, HOAc 
35 
H 0 
II 11/0Ph 
Bz!O~NYP'-... 
II OPh 
0 R 40 
Peptide derivatives can then prepared by sequential cou-
pling of N-blocked amino acids using the DCC coupling 
method according to the scheme below. For example H-Phe-
Leu-PheP(OPh)2 was prepared by coupling H-PheP(OPh)2 45 
to Cbz-Leu-OH followed by removal of the Cbz group then 
coupling to Cbz-Phe-OH and finally removal of the protect-
ing group. H-Ala-Ala-AlaP(OPh)2 and H-Ala-Ala-Mer (0Ph)2 were prepared in the same way by coupling H-AlaP 
(0Ph)2 and H-MetP(OPh)2, respectively to Cbz-Ala-OH 50 
followed by deblocking, coupling with Cbz-Ala-OH, and 
deblocking. H-Val-Pro-ValP(OPh)2 was prepared from 
H-van0Ph)2 by coupling with Cbz-Pro-OH, deblocking, 
coupling with Cbz-Val-OH, and then deblocking. 
H 0 I 11/0Ph 
Bz!O~NYP'-
11 OPh 
0 R 
a) HBr/HOAc 
b) coupling with blocked 
peptide acid or 
sequential coupling 
with blocked amino 
acid deriviatives 
Peptidyl - AAP(OPh)2 
55 
60 
Fluorescein amine is coupled to monomethyl adipoate 65 
followed by saponification of the ester group to give Fla-
Adp-OH. 
12 
1. HOCO - (CH2)4 - COO Me 
HO 
2. Off, H+ 
Flouresceinamine 
HO 0 
Fla-Adp-OH 
0 
This intermediate can be coupled to the amino acid or 
peptide phosphonate unit using the DCC coupling method as 
shown in the scheme below. 
Examples of Attachment of the Fla-Adp- Units to 
Peptide Phosphonates 
Fla-Adp-OH + peptidephosphonate 
Fla - Adp - peptide phosphonate 
Fla-Adp-OH + PheP(OPh)2 couple 
Example of Attachment of the Fluor-Spacer Unit to 
an Amino Acid Phosphonate 
Fla-Adp-OH + 
+ 
couple 
-
H1N NH2 c1-
H-(4-AmpPhGly)P(OPh)2 
5,916,877 
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-continued 
Fla-Adp-HN 
0 
11,.....oPh 
p 
°'oPh 
14 
dissolved in EtOAc and washed with sat. NaCL After drying 
with Na2S04 and removal of the solvent, the residue was 
triturated with ethyl ether to give Fla-Adp-OH as a yellow 
solid: yield 91%; one spot on TLC (R1=0.16, 5 CHCl3 :MeOH:HOAc, 90:10:1); high-resolution FAE-MS, 
m/e (M+H) calcd for 476.1345, found 476.1306. Anal. Calcd 
for C26H21N08 0.5H20: C, 64.27; H, 4.58; N, 2.89. Found: 
10 
H2N NH2 c1-
Fla -Adp-( 4-AmpPhGly)P(OPh)2 
The following examples are given to illustrate the invention 15 
and are not intended to limit it in any manner. 
General Synthesis Procedures 
C, 64.40; H, 4.94; N, 2.58. 
EXAMPLE 2 
Diphenyl N-(N-(5-Fluoresceinyl)-5-
carbamoy lpentanoy l)amino( 4-amidinophenyl) 
methanephosphonate Hydrochloride {Fla-Adp-( 4-
AmPhGlyt(OPh)2}. 
Fla-Adp-OH (38 mg, 79 µmol) and the dihydrochloride of 
( 4-amidinophenyl)aminomethanephosphonate (36 mg, 79 
µmol) were dissolved in 2 mL of DMF followed by addition 
5-Fluoresceinamine, adipic acid monomethyl ester, and 20 of 1 equiv of TEA HOBt (16 mg, 1.5 equiv) and EDC.HCl 
(18 mg, 1.2 equiv) were added and the mixture was stirred 
at rt overnight. The solvent was removed in vacuo, and the 
residue was purified on a silica gel column eluted with 
CHCl3 :MeOH:HOAc (40:10:1). Fractions containing the 25 
all common reagents and solvents were purchased from 
Aldrich Chemical Company, Milwaukee, Wis. Porcine pan-
creatic elastase (PPE) was obtained from United States 
Biochemical Corp., Cleveland, Ohio. Human leukocyte 
elastase (HLE) was obtained from Athens Research and 
Technology, Inc., Athens, Ga. Hepes was obtained from 
Research Organics, Inc., Cleveland, Ohio. Bovine trypsin 
was purchased from Sigma Chemical Company, St. Louis, 
Mo. Preparative thin-layer chromatography was performed 
with plates precoated with 2 mm of silica gel G.F. and were 
obtained from EM Separations, Gibbstown, N.J. 08027. 
NMR spectra were recorded on a Varian GEMINI 300. 
Elemental analyses were performed by the Atlantic 
Microlabs, Atlanta, Ga. Diphenyl 1-(N-dipeptidylamino) 35 
alkanephosphonate esters were synthesized as previously 
described (Oleksyszyn and Powers, Biochemistry, 1991, 30, 
485-493). 
desired product were collected and concentrated under 
reduced pressure. Ethyl ether was added to give a yellow 
solid: yield 54%; one spot on TLC (R1=0.20, 
CHCl3 :MeOH:HOAc, 40:10:1); high-resolution FAE-MS, 
30 m/e (M+H) calcd for 839.2482, found 839.2525. 
EXAMPLE 3 
W-(N-(5-Fluoresceinyl)-5-carbamoylpentanoyl)-E-
tert-butyloxycabonyllysine {Fla-Adp-Lys(Boc)-
OH}. 
E-tert-Butyloxycarbonyllysine methyl ester hydrochloride 
(65 mg, 210 µmol) was dissolved in 3 ml of DMF. After 
neutralization by 1 equiv of TEA, Fla-Adp-OH (100 mg, 210 
EXAMPLE 1 
N-Adipoyl-5-aminofiuorescein {Fla-Adp-OH}. 
40 µmol) and 1 equiv of EDC.HCl were added and the mixture 
was stirred at rt overnight. The solvent was removed in 
vacuo, and the residue was dissolved in EtOAc. The EtOAc 
layer was washed with 10% citric acid and sat. NaCL After Adipic acid monomethylester (0.17 mL, 0.58 mmol) was 
dissolved in 2 mL of DMF and kept at -10° C. Thionyl 
chloride (0.10 mL, 1.4 mmol) was added and stirred for 10 
min at -10° C. A solution of 5-fiuoresceinamine in 2 mL of 
DMF was added and stirred overnight. The solvent was 
removed in vacuo. The residue was dissolved in EtOAc. The 
EtOAc layer was washed with 10% citric acid, water, and 
sat. NaCL After drying with Na2S04 and removal of the 
solvent, the residue was purified on a silica gel column 
eluted with CHCl3 :MeOH (7:1). Fractions with R_r0.31 
were collected and concentrated to give an orange oily 55 
residue. Ethyl ether was added to give Fla-Adp-OMe as a 
yellow solid: yield 29%; one spot on TLC (R_r0.46, 
CHCl3 :MeOH:HOAc, 90:10:1); MS (FAE+) m/e 490 
(M+H). 
45 drying with Na2S04 and removal of the solvent, ethyl ether 
was added to give a yellow solid: yield 55%; one spot on 
TLC (R_r0.33, CHCl3 :MeOH:HOAc (90:10:1)); MS 
(FAE+) m/e 718 (M+H). 
Fla-Adp-Lys(Boc)-OMe (50 mg, 70 µmol) was dissolved 
50 in 2 mL of DMF. A solution of 1 N NaOH (0.35 ml) was 
added and the mixture was stirred at rt for 6 hours. The 
Fla-Adp-OMe (95 mg, 0.19 mmol) was dissolved in 2 mL 60 
ofMeOH.Asolution of 1 NNaOH (0.58 mL) was added and 
the mixture was stirred at rt overnight. Most of the MeOH 
was removed under reduced pressure, and the aqueous 
solution was placed in an ice bath. Diluted HCl were added 65 
dropwise with stirring until the mixture was acidic (pH=2-3) 
and an orange solid precipitated. The orange supension was 
solvent was removed in vacuo, and 10% citric acid was 
added to the residue in an ice bath until the mixture was 
acidic (pH=2-3). The desired product was extracted with 
EtOAc and washed with sat. NaCL After drying with 
Na2S04 and removal of the solvent, ethyl ether was added 
to give a yellow solid: yield 93%; MS (FAE+) m/e 704 
(M+H). 
EXAMPLE 4 
Diphenyl {N-Adipoyl-5-aminofiuoresceinyl-L-
lysylamino }( 4-amidinophenyl)methanephosphonate 
{Fla-Adp-Lys-(AmPhGlyt{OPh)2}. 
Fla-Adp-Lys(Boc)-OH (50 mg, 70 µmol) and 
(4-AmPhGlyt(OPh)2·2HCl (32 mg, 70 µmol) were dis-
5,916,877 
15 
solved in 3 mL of DMF followed by addition of 1 equiv of 
TEA HOBt (14 mg, 1.5 equiv) and EDC.HCl (16 mg, 1.2 
equiv) were added and the mixture was stirred at rt over-
night. The solvent was removed in vacuo, and the residue 5 
was purified on a silica gel column eluted with 
CHCl3 :MeOH:HOAc (40:10:1). Fractions containg the 
desired product were collected and concentrated under 
reduced pressure. Ethyl ether was added to give a yellow 
10 
solid: yield 47%; high-resolution FAE-MS, m/e (M+H) 
calcd for 1067.3956, found 1067.3929. 
Fla-Adp-Lys(Boc)-( 4-AmPhGlyt{OPh)2 (30 mg, 27 
mmol) was dissolved in 1 mL of TFA After 30 min 15 
treatment at rt, the solvent was removed under reduced 
pressure. Ethyl ether was added to the residue to give a 
yellow solid: yield 77%; high-resolution FAE-MS, m/e 
(M+H) calcd 967.3472, found 967.3408. 
20 
EXAMPLE 5 
N-Adipoyl-5-aminofiuoresceinyl-L-threonine {Fla-
Adp-Thr-OH}. 25 
L-Threonine methylester hydrochloride (37 mg, 210 
µmol) was dissolved in 3 mL of DMF. After neutralization 
by 1 equiv of TEA, Fla-Adp-OH (100 mg, 210 µmol) and 1.2 
equiv of EDC HCl were added and the mixture was stirred 30 
at rt overnight. The solvent was removed in vacuo. The 
residue was dissolved in EtOAc and washed with 10% citric 
acid, water, and sat. NaCL After drying with Na2S04 and 
removal of the solvent, ethyl ether was added to give a 
yellow solid: yield 53%; one spot on TLC (R_r0.16, 35 
CHCl3 :MeOH:HOAc, 90:10:1); MS (FAE+) m/e 591 
(M+H). 
Fla-Adp-Thr-OMe (67 mg, 110 µmol) was dissolved in 2 
mL of DMF. A solution of 1 N NaOH (0.55 mL) was added 
and the mixture was stirred at rt for 6 hours. The solvent was 40 
removed in vacuo, and 10% citric acid was added to the 
residue in an ice bath until the mixture was acidic (pH=2-3). 
The desired product was extracted with EtOAc and washed 
with sat. NaCL After drying with Na2S04 and removal of the 
solvent, ethyl ether was added to give a yellow solid: yield 45 
83%; MS (FAE+) m/e 577 (M+H). 
EXAMPLE 6 
Diphenyl {N-adipoyl-5-aminofiuoresceinyl-L-
threonylamino }( 4-amidinophenyl) 
methanephosphonated hydrochloride {Fla-Adp-Thr-
( 4-AmPhGlyt(OPh)2. 
50 
55 
Fla-Adp-Thr-OH (45 mg, 78 µmol) and (4-AmPhGly)2 
(0Ph)2·2HC1 (35 mg, 78 µmol) were dissolved in 3 mL of 
DMF followed by addition of 1 equiv of TEA HOBt (16 
mg, 1.5 equiv) and EDC HCl (18 mg, 1.2 equiv) were added 
and the mixture was stirred at rt overnight. The solvent was 60 
removed in vacuo, and the residue was purified on a silica 
gel column eluted with CHCl3 :MeOH:HOAc (35:15:1). 
Fractions containing the desired product were collected and 
16 
What is claimed is: 
1. A compound of the formula: 
R 
~/z 
Fluor-NHCO-Spacer-AA3-AA2-N P 
I 11'z1 
H 0 
or an acceptable salt, wherein 
Fluor is selected from the group consisting of 
(a) 
HO 0 
(5-Substituted Fluorescein) 
(b) 
HO 0 
(6-Substituted Fluorescein) 
(c) 
(5-Substituted Tetramethylrhodamine) 
(d) 
concentrated under reduced pressure. Ethyl ether was added (cH
3
)
2
N w (cH
3
)
2 
to give a yellow solid: yield 32 mg; one spot on TLC, 65 (6-Substituted Tetramethylrhodamine) 
R_r0.33, CHCl3 :MeOH:HOAc (35:15:1); high-resolution 
FAE-MS, m/e (M+H) calcd for 940.2959, found 940.2984. 
5,916,877 
17 
-continued 
(e) 
5 
18 
sulfone, phenylalanine, tryptophan, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 
ornithine, homolysine, and homoarginine, and 
(b) phenyl substituted with B, benzyl substituted with 
B on the phenyl, and C1_6 alkyl substituted with B, 
10 B is selected from the group consisting of amidino 
and 
(5-Substituted Texas Red) 15 
(!) 
20 
25 
(6-Substituted Texas Red) 
30 
(g) an aromatic fluorescent group with an em1ss10n 
maximum of 350 to 700 nm, 35 
Y is selected from the group consisting of H, COOH, 
and S03H, 
Spacer is selected form the group consisting of 
(a)-CH2 CH2-CH2-CH2-CO-, 40 
(b) ---(CH2)n-CO-, 
where n=l to 12, 
AA3 and AA2 are the same or different and are selected 
independently from the group consisting of 
(a) a single bond, 
45 
(b) an amino acid residue selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, methion- 50 
ine sulfone, phenylalanine, tryptophan, serine, 
threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, norleucine, norvaline, 
alpha-aminobutyric acid, citrulline, hydroxyproline, 55 
ornithine, homolysine, and homoarginine; wherein 
said amino acid residue is of the D- or L-
configuration, and wherein the side chain of said 
amino acid is optionally blocked, and 
(c) glycine, sarcosine, epsilon-aminocaproic acid, and 60 
beta-alanine; 
R is selected from the from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
side chain selected from the group consisting of 65 
glycine, alanine, valine, leucine, isoleucine, praline, 
methionine, methionine sulfoxide, methionine 
(-C(=NH)NH2), guanidino (-NH-C(=NH) 
NH2), isothiureido (-S-C(=NH)NH2), and 
amino; 
Z and Z1 are the same or different and are selected 
independently from the group consisting of 
phenoxy, phenoxy substituted with J, phenoxy 
disubstituted with J, phenoxy trisubstituted with J, 
halogen, and c1-6alkoxy, and 
J is selected from the group consisting of halogen, 
cl-6 alkyl, cl-6 perfiuoroalkyl, c1-6alkoxy, and 
CN; 
with the proviso that Z and Z1 cannot simultaneously 
be cl-6 alkoxy. 
2. A compound according to claim 1 wherein 
Fluor is the structure 
HO 0 
3. A compound according to claim 2 wherein 
Yis COOH, 
Spacer is -CH2-CH2-CH2-CH2-CO-, 
AA3 and AA2 are the same or different and are selected 
independently from the group consisting of 
(a) a single bond, 
(b) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, lysine, threonine, methionine, 
phenylalanine, and praline, 
R is selected from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
residue selected from the group consisting of 
alanine, valine, leucine, isoleucine, methionine, 
phenylalanine, aspartic acid, lysine, arginine, and 
phenylglycine, 
(b) a phenyl group substituted with B, 
B is amidino, and 
Z and Z1 are the same or different and are selected 
independently from the group consisting of phenoxy or 
phenoxy substituted with a halogen. 
4. A compound according to claim 1 wherein 
19 
Fluor is the structure 
5,916,877 
5 
10 
15 
20 
AA3 and AA2 are the same or different and are selected 
independently from the group consisting of 
(a) a single bond, 
(b) a blocked or unblocked amino acid residue with the 
L or D configuration at the a-carbon selected from 
the group consisting of alanine, valine, leucine, 
isoleucine, lysine, threonine, methionine, 
phenylalanine, and praline, 
R is selected from the group consisting of 
(a) the side chain of a blocked or unblocked amino acid 
side chain selected from the group consisting of 
alanine, valine, leucine, isoleucine, metlionine, 
phenylalanine, aspartic acid, lysine, arginine, and 
phenylglycine, 
(b) a phenyl group substituted with B, 
B is amidino, and 
5. A compound according to claim 4 wherein 
Y is S03H, 
Z and Z1 are the same or different and are selected 
independently from the group consisting of phenoxy or 
phenoxy substituted with a halogen. 
6. A compound or an acceptable salt of the compound 
selected from the group of structures consisting of Spacer is -CH2-CH2-CH2-CH2-CO-, 
(a) 
NH- CO- CH2- CH2-CH2- CH2-CO- PheP(OPh)2 
COOH 
HO 0 
(Fla - Adp- PheP(OPh)2) 
(b) 
NH-CO-CH2-CH2-CH2-CH2-C0-(4-AmPhGly)P(OPh)2 
COOH 
HO 0 
(Fla - Adp-( 4-AmPhGly)P(OPh)2) 
NH-CO-CH2-CH2-CH2-CH2-CO-Lys-(4-AmPhGly)P(OPh)2 (c) 
HO 0 
(Fla - Adp - Lys-( 4-AmPhGly)P(OPh)2) 
5,916,877 
21 22 
-continued 
NH-CO-CH2-CH2-CH2-CH2-CO-Lys(Boc)-(4-AmPhGly)P(OPh)2 
(d) 
HO 0 
(Fla -Adp-Lys(Boc)-(4-AmPhGly)P(OPh)2). 
NH-CO-CH2-CH2-CH2-CH2-CO-Thr-(4-AmPhGly)P(OPh)2 (e) 
HO 0 
(Fla - Adp-Thr-( 4-AmPhGly)P(OPh)2). 
7. A compound according to claim 1 wherein AA3 is a 30 
sidechain unblocked amino acid residue with the L configu-
ration at the a-carbon. 
14. A compound according to claim 1 wherein AA2 is a 
sidechain blocked amino acid residue with the D configu-
ration at the a-carbon. 
15. A compound according to claim 1 wherein AA3 and 
AA2 are the same. 
8. A compound according to claim 1 wherein AA3 is a 
sidechain unblocked amino acid residue with the D configu-
ration at the a-carbon. 
9. A compound according to claim 1 wherein AA3 is a 
sidechain blocked amino acid residue with the L configu-
ration at the a-carbon. 
35 16. A compound according to claim 1 wherein AA
3 and 
AA2 are different. 
17. A compound according to claim 1 wherein Z and Z1 
are the same. 
10. A compound according to claim 1 wherein AA3 is a 
sidechain blocked amino acid residue with the D configu-
ration at the a-carbon. 
18. A compound according to claim 1 wherein Z and Z1 
40 are different. 
11. A compound according to claim 1 wherein AA2 is a 
sidechain unblocked amino acid residue with the L configu-
ration at the a-carbon. 
12. A compound according to claim 1 wherein AA2 is a 45 
sidechain unblocked amino acid residue with the D configu-
ration at the a-carbon. 
13. A compound according to claim 1 wherein AA2 is a 
sidechain blocked amino acid residue with the L configu-
ration at the a-carbon. 
19. A method for detecting the presence of a serine 
protease in cells, plasma, and other biological media, com-
prising contacting the serine protease with a compound 
according to claim 1. 
20. A method for inhibiting a serine protease that is 
present in cells, plasma, or other biological media, compris-
ing contacting the serine protease with a compound accord-
ing to claim 1. 
* * * * * 
